From: The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study
 | Time period of first diagnosis | |||||||
---|---|---|---|---|---|---|---|---|
 | 1982-1986 | 1987-1991 | 1992-1996 | 1997-2001 | ||||
First primary cancer | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) |
   Head and neck | 165 | 1.92 (1.64-2.23) | 204 | 1.88 (1.63-2.16) | 271 | 1.98 (1.75-2.23) | 255 | 1.93 (1.70-2.18) |
   Oesophagus | 8 | 1.53 (0.66-3.02) | 10 | 0.90 (0.43-1.66) | 23 | 1.60 (1.01-2.39) | 23 | 1.19 (0.76-1.79) |
   Stomach | 18 | 0.75 (0.44-1.18) | 27 | 1.02 (0.67-1.49) | 30 | 0.91 (0.62-1.31) | 36 | 1.09 (0.76-1.51) |
   Colorectal | 198 | 0.89 (0.77-1.02) | 273 | 0.95 (0.84-1.07) | 411 | 1.07 (0.97-1.18) | 559 | 1.20 (1.11-1.31) |
   Pancreas | 7 | 1.20 (0.48-2.47) | 5 | 0.61 (0.20-1.42) | 10 | 0.98 (0.47-1.81) | 12 | 0.83 (0.43-1.45) |
   Lung | 71 | 1.06 (0.83-1.34) | 93 | 1.14 (0.92-1.40) | 147 | 1.61 (1.36-1.89) | 148 | 1.30 (1.10-1.53) |
   Melanoma | 311 | 1.81 (1.62-2.02) | 471 | 1.89 (1.72-2.07) | 639 | 2.04 (1.88-2.20) | 835 | 2.02 (1.89-2.16) |
   Breast - female | 152 | 0.97 (0.82-1.14) | 199 | 0.94 (0.81-1.08) | 359 | 1.32 (1.19-1.47) | 504 | 1.37 (1.25-1.50) |
   Cervix | 24 | 1.29 (0.83-1.92) | 38 | 1.88 (1.33-2.58) | 34 | 1.64 (1.14-2.29) | 26 | 1.55 (1.01-2.27) |
   Uterus | 30 | 1.14 (0.77-1.63) | 35 | 1.18 (0.82-1.64) | 35 | 0.87 (0.60-1.21) | 63 | 1.30 (0.99-1.66) |
   Ovary | 16 | 1.36 (0.78-2.20) | 10 | 0.64 (0.31-1.18) | 26 | 1.35 (0.88-1.98) | 24 | 1.02 (0.66-1.52) |
   Prostate | 163 | 0.64 (0.54-0.74) | 291 | 0.76 (0.68-0.85) | 603 | 0.84 (0.77-0.91) | 655 | 0.95 (0.88-1.02) |
   Kidney | 44 | 1.48 (1.08-1.99) | 73 | 1.79 (1.40-2.25) | 92 | 1.53 (1.24-1.88) | 160 | 2.04 (1.74-2.38) |
   Bladder | 137 | 1.46 (1.22-1.72) | 189 | 1.78 (1.53-2.05) | 238 | 1.84 (1.61-2.09) | 353 | 2.22 (2.00-2.47) |
   Brain & CNS | -- | -- | 5 | 1.00 (0.33-2.34) | -- | -- | 9 | 1.10 (0.50-2.09) |
   Thyroid | 9 | 1.25 (0.57-2.38) | 12 | 1.25 (0.64-2.18) | 29 | 1.64 (1.10-2.36) | 46 | 1.67 (1.22-2.23) |
   Non-Hodgkin lymphoma | 42 | 1.09 (0.79-1.48) | 62 | 1.15 (0.88-1.48) | 88 | 1.25 (1.00-1.54) | 144 | 1.49 (1.25-1.75) |
   Lymphoid leukaemia | 24 | 1.00 (0.64-1.48) | 33 | 1.25 (0.86-1.75) | 63 | 1.68 (1.29-2.15) | 88 | 1.71 (1.37-2.10) |
   Myeloid leukaemia | 13 | 1.23 (0.66-2.11) | 11 | 0.91 (0.45-1.62) | 26 | 1.52 (0.99-2.22) | 34 | 2.05 (1.42-2.86) |
   Myeloma/PCT | 21 | 1.37 (0.85-2.10) | 7 | 0.46 (0.19-0.95) | 19 | 0.83 (0.50-1.29) | 39 | 1.05 (0.75-1.44) |
   Other | 79 | 0.94 (0.74-1.17) | 136 | 1.22 (1.03-1.45) | 241 | 1.43 (1.26-1.62) | 318 | 1.43 (1.28-1.60) |
   All cancers combined | 1,534 | 1.14 (1.08-1.20) | 2,184 | 1.22 (1.17-1.28) | 3,386 | 1.36 (1.31-1.41) | 4,331 | 1.46 (1.41-1.50) |